We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.71 | 0.49% | 146.45 | 146.76 | 144.54 | 146.01 | 2,198,069 | 16:35:55 |
From Apr 2019 to Apr 2024
By Matt Grossman
Johnson & Johnson Tuesday revised its full-year forecast, pointing to slightly higher sales and profit figures than the company had previously indicated.
J&J said it now estimates 2020 reported sales will be between $81.2 billion and $82 billion, which represents a range of a 1% decline to flat compared with last year's results. In July, J&J said it expected reported sales to decline between 0.8% and 2.6% year over year.
The New Brunswick, N.J.-based health-care company said it now expects adjusted earnings per share of between $7.95 and $8.05 for the full year. The company had previously forecast adjusted earnings per share of $7.75 to $7.95.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
October 13, 2020 07:20 ET (11:20 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
